Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 8/20 | 0.45 |
| ▸ | F2 | P00734 | 4/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4685301 | 0.91 | F10 (0.48) | F10F2TAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL4684495 | 0.90 | F10 (0.41) | F10F2TAS1R3TAS1R1PRSS1 | |
| SCHEMBL4681065 | 0.88 | F10 (0.40) | F10F2TAS1R3TAS1R1PRSS1 | |
| SCHEMBL4682219 | 0.84 | F10 (0.46) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL4685331 | 0.82 | F10 (0.46) | F10F2PRSS1 | |
| Trifluoroacetic Acid SCHEMBL4684485 | 0.81 | F10 (0.44) | F10F2TAS1R3TAS1R1PRSS1 | |
| SCHEMBL4685823 | 0.81 | F10 (0.42) | F10F2SMN1; SMN2 | |
| SCHEMBL4687811 | 0.80 | F10 (0.43) | F10F2 | |
| SCHEMBL4685327 | 0.79 | F10 (0.47) | F10F2PRSS1PRSS2PRSS3 | |
| Trifluoroacetic Acid SCHEMBL4681055 | 0.79 | F10 (0.43) | F10F2TAS1R3TAS1R1PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1236712-B1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | AJINOMOTO KK (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-6710056-B2 | PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. | AJINOMOTO CO., INC. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | AJINOMOTO CO. INC (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1236712-A1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | HABP2, F2, F7 | F10 26/4885F2 2/4885TAS1R3 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.